MEM-288 (solid tumors) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called MEM-288 (the study drug) is a safe and effective treatment for your cancer.
What is the Condition Being Studied?
Advanced Solid Tumors
Who Can Participate in the Study?
Adults diagnosed with the following cancers that have spread:
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous-cell carcinoma (cSCC)
- Merkel cell carcinoma
- Melanoma
- Triple negative breast cancer (TNBC)
- Pancreatic cancer
- Head and neck cancer
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take the study drug (MEM-288)
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and MRI)
- Have heart tests (ECG)
Study Details
Full Title
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination with Nivolumab in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Head and Neck Oncologist
Protocol Number
IRB:
PRO00109517
NCT:
NCT05076760
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-681-6468